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Abstract
Background:Central nervous system irradiation (CNS-RT) has played a central role in the cure of
acute lymphoblastic leukemia (ALL), but due to the risk of long-term toxicity, it is now considered
a less-favorable method of CNS-directed therapy.
Procedures: Retrospectively, we estimated the effect of CNS involvement and CNS-RT on events
and overall survival (OS) in 835 children treated for high-risk ALL in the Nordic Society of Paedi-
atric Haematology andOncology (NOPHO) ALL-92 and ALL-2000 trials.
Results:We did not observe a statistically significant difference in the OS or event-free survival
(EFS) in patients with CNS involvement at diagnosis, but the risk of isolated CNS relapse was
higher (hazard ratio [HR] 7.09, P < 0.001). CNS-RT was given to 169 of the 783 patients in first
complete remission, of which 16 had CNS involvement at diagnosis. In general, CNS-RT improved
EFS (HR 0.58, P < 0.05) but not OS (HR 0.69, P = n.s.). The adjusted HRs for all relapses, isolated
bonemarrow relapse, CNS-involving relapse, and isolated CNS relapse, were 0.47 (P< 0.01), 0.50
(P< 0.05), 0.34 (P< 0.01), and 0.12 (P< 0.01), respectively, in irradiated patients.
Conclusions: CNS-RT was associated with an advantage in EFS by decreasing the risk of relapse
but without improving OS.
K EYWORDS
acute lymphoblastic leukemia, children, central nervous system, irradiation, risk factor
ABBREVIATIONS: ALL, acute lymphoblastic leukemia; BM, bonemarrow; CNS, central
nervous system; CNS1-2, no central nervous system leukemia; CNS3, central nervous system
leukemia; CNS-RT, central nervous system irradiation; CR1, first complete remission; CSF,
cerebrospinal fluid; DCR1, death in first complete remission; EFS, event-free survival; EI,
extra-intensive; HR, hazard ratio; HSCT, hematopoietic stem cell transplantation; IT,
intrathecal; MLL, mixed-lineage leukemia; MRD, minimal residual disease;MTX,
methotrexate; NOPHO, Nordic Society for Paediatric Haematology andOncology; OS, overall
survival; SMN, secondmalignant neoplasm; T-ALL, T-cell acute lymphoblastic leukemia; VHR,
very high risk; VI, very intensive;WBC, white blood cell count
1 INTRODUCTION
The survival of children with acute lymphoblastic leukemia (ALL)
has improved over the last five decades from anecdotal cases to
above 90% in the best contemporary clinically and biologically risk-
stratified treatment programs.1–3 The therapy has been increasingly
risk-adapted using biological features of leukemia,4 sensitive methods
formeasurement of the response to therapy,5 and exploiting improved
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understanding of the pharmacology of antileukemic agents. Since a
large fraction of patients in early trials suffered central nervous sys-
tem (CNS) relapses, an important part of a comprehensive approach is
CNS-directed prophylactic therapy.6–8
The CNS and the testicles are pharmacological sanctuaries of
leukemic cells. With advances in modern ALL treatment, testicular
relapses are now very uncommon. Although the frequency of CNS
relapses has decreased, they remain a clinical challenge. A majority of
patients who relapse in the CNS also have bone marrow (BM) involve-
ment, at least on theminimal residual disease (MRD) level.9 Before the
addition of CNS-directed therapy, 50% of all patients relapsed in the
CNS,1,6 but on contemporary ALL-protocols with CNS-directed pro-
phylactic therapy, CNS-involving relapses occur in only 4–5% of the
patients.2,10
The most commonly applied approaches to CNS-directed therapy
have been CNS irradiation (CNS-RT), intrathecal (IT) chemotherapy
with methotrexate (MTX), or IT triples (MTX, prednisolone, cytara-
bine). In addition, systemic high-dose chemotherapy with MTX or
cytarabine is frequently used,1 although the impact is uncertain.11
Cure rate from childhood ALL was at 15–20% before the era of pro-
phylactic CNS-directed therapy but improved with development of
systemic and IT chemotherapy and prophylactic CNS-RT.6 Along with
the development of ALL treatment, the doses of prophylactic CNS-
RT have been reduced and even omitted from some of the most
recent ALL protocols.7,10,12,13 At the same time, dexamethasone,14
asparaginase,15 and 6-thioguanine16 have played a role in the systemic
approach to CNS-directed therapy.
The aims of this study were to evaluate the impact of CNS involve-
ment at diagnosis (central nervous system leukemia [CNS3]) and CNS-
RT on the risk of adverse events and overall outcome in high-risk ALL-
patients treated on the Nordic Society of Paediatric Haematology and
Oncology (NOPHO) ALL-92 and ALL-2000 protocols.
2 PATIENTS AND METHODS
TheNOPHOALL-92 and ALL-2000 studies were open for recruitment
from January 1992 to October 2001 and from January 2002 to July
2008, respectively. Both protocols included patients from the age of
1.0 up to 14.9 years. Altogether, 2,735 children with ALL were treated
on the NOPHO ALL-92 (N = 1,644) and ALL-2000 protocols (N =
1,091) in the fiveNordic countries (Denmark, Finland, Iceland,Norway,
and Sweden).10 Of these, 836 patients were stratified to the high-risk
arms, including 462 ALL-92 and 374 ALL-2000 patients (Fig. 1). One
patient did not have CNS status registered and was excluded from the
study cohort resulting in 835 high-risk patients in the analyses. The
median follow-up timewas 7.8 (range 0.07–20.9) years.
2.1 The definition of the CNS status
CNS3 was defined as an elevated cerebrospinal fluid (CSF) white
blood cell count (WBC) (≥5 mononuclear cells/𝜇l) and a cytospin
preparation demonstrating leukemic blasts. CNS3 was also diagnosed
when the CSF leukocyte count was normal, but clinical (cranial nerve
ALL-92
N=1,644
CNS-RT
n=153
CNS3
n=52
CNS1-2
n=731
High-risk
n=835
Induction failure
n=52 (CNS3 n=4)
Total
n=2,735
ALL-2000
n=1,091
CNS-RT
n=16
Missing data on 
CNS status 
n=1
F IGURE 1 Patient population of the study. High-risk patients
treated on the NOPHO ALL-92 and ALL-2000 protocols were evalu-
ated focusing on CNS3 (N= 56) and CNS-RT (N=169) as risk factors of
survival. Three of the nonirradiated patientswere censored at the time
of HSCT in the CNS-RT analyses
palsy) or neuroimaging signs (two patient diagnosed solely by imag-
ing and symptoms and no blast in the CSF) of CNS involvement
were present. CNS3 diagnoses have been re-evaluated by one of the
researchers (ML).
2.2 High-risk criteria
CNS3 status at diagnosis stratified the patient into the high-risk
therapy in both NOPHO ALL-92 and ALL-2000 protocols.10 The
other high-risk criteria for both protocol cohorts were WBC ≥50 ×
109 l–1, T-cell immunophenotype, lymphomatous features, testicular
leukemia, or slow response (day 15marrowM3 and/or day 29marrow
≥M2). The stratifying high-risk cytogenetics in the ALL-92 protocol
were t(9;22)(q34;q11), mixed-lineage leukemia (MLL) rearrangements
(11q23), (22q-), t(8;14)(q24;q32), t(2;8)(p12;q24), or t(8;22)(q24;q11)
and in the ALL-2000 protocol were t(9;22)(q34;q11), t(4;11)(q21;q23),
t(1;19)(q23;p13.3), and hypodiploidy (modal chromosomal number
<45).
The three high-risk subgroups in the ALL-92 protocol erawere very
high risk (VHR, age ≥5 years with CNS3, poor early response, or T-cell
acute lymphoblastic leukemia [T-ALL] with another high-risk feature),
high-risk-1 (age <5 years and high risk) and high-risk-2 (rest of the
high-risk patients). The ALL-2000 protocol also included three high-
risk subgroups, which were extra-intensive (high-risk-EI, any age and
high-risk cytogenetics, poor early response, or WBC >200×109 l–1),
very intensive group (high-risk-VI, age ≥5 years and CNS3, T-ALL, or
WBC 100–200 × 109 l–1), and intensive group (high-risk I, rest of the
high-risk patients).
2.3 Systemic chemotherapy
Both protocols had a three-drug induction (prednisolone at 60mg/m2,
four vincristine injections at 2.0 mg/m2, and two [ALL-2000] to four
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[ALL-92] doxorubicin infusions at 40 mg/m2) followed by a con-
solidation with alternating high-dose MTX (8 g/m2) and high-dose
cytarabine (12 g/m2) and a delayed intensification.10 In addition, the
ALL-2000 protocol had an early intensification phase (cyclophos-
phamide, 6-thioguanine, and low-dose cytarabine) before the consol-
idation. The maintenance therapy in the ALL-92 protocol consisted of
oral 6-mercaptopurine and MTX combined with pulses of vincristine
and prednisone. However, all VHR ALL-92 patients and all (N = 98)
Finnish high-risk-1 and high-risk-2 ALL-92 patients (as part of a pilot
cohort) were given LSA2L2 maintenance therapy throughout their
maintenance therapy.17 The maintenance therapy in the ALL-2000
protocol (high-risk-I and high-risk-VI patients) included two cycles of
LSA2L2 regimen (with cycling pulses of thioguanine plus cyclophos-
phamide, hydroxyurea plus daunorubicin, peroral methotreaxate plus
carmustine, and cytrarabine plus vincristine) followed by per oral 6-
mercaptopurine andMTX combinedwith pulses of vincristine and dex-
amethasone. The total duration of the therapy was 104 weeks in both
protocols.10
2.4 CNS-directed therapy (prophylaxis and CNS3
therapy)
MTX was used in the IT prophylactic therapy. The cumulative number
of the IT injections varied from eight (ALL-2000 high-risk-EI) to 17
(ALL-92 high-risk VHR). Patients with CNS3 were given additional IT
triple chemotherapy in the induction until clearance of CNS blasts.
Patients older than 5 years with WBC 100 × 109 l–1 or more or
T-cell immunophenotype with lymphomatous features (ALL-92 VHR
and ALL-2000 high-risk-VI) received prophylactic cranial irradiation
(Table 1).10 All patients less than 5 years of age and patients 5 years
or older but with WBC less than 100 × 109 l–1 (ALL-92 high-risk-1
and high-risk-2, ALL-2000 high-risk-I) received no prophylactic CNS-
RT, but instead twoadditional coursesof bothhigh-doseMTXandhigh-
dose cytarabine. CNS3patients treatedonALL-92protocolwere given
craniospinal irradiation. In the ALL-2000 protocol, no irradiation was
given to CNS3 patients less than 5 years of age, but cranial irradiation
was given to the CNS3 patients aged at least 5 years.
The protocol time for CNS-RT was slightly different in the NOPHO
ALL-92 and 2000 protocols, that is, days 308 and 259, respectively.
A major problem in this study was to address the issue of proto-
col adherence to the recommendations for CNS-RT. Thirteen patients
received CNS-RT, although the protocol did not recommend it and 72
patients did not receive CNS-RT despite protocol recommendations
(Supplementary Table S1). There were country-specific differences in
the use of CNS-RT and individual interpretations of the recommenda-
tions. During the trial periods, the cumulative evidence for the adverse
effects of CNS-RTmade CNS-RT a less attractive treatment option for
many clinicians. Among the patients included in the outcome analy-
ses (n = 783), 110 underwent hematopoietic stem cell transplantation
(HSCT) in first complete remission (CR1); three of them received CNS-
RT before starting the conditioning process.
2.5 Statistical analyses
The analyses were performed based on the therapy given in each case.
Baseline variables were compared between the two protocols using
Fisher exact tests for categorical variables and the Mann–Whitney
U-test for continuous variables. The Kaplan–Meier method was used
for generating event-free (EFS) and overall survival (OS) estimates.
Relapse, death in first complete remission (DCR1) and second malig-
nancy (SMN) were classified as events. We chose the protocol recom-
mendations as the landmark time in the Kaplan–Meier survival anal-
yses. Accordingly, ALL-92 patients with any event occurring before
308 days and ALL-2000 patients before 259 days were excluded from
the Kaplan–Meier analyses concerning the impact of irradiation. This
adjusts for the overestimation of effect of CNS-RT on survival, since
patientswhodieor have relapsesbefore the landmark timewouldhave
a negative impact on the comparison group. Two-sided log-rank test
was used for comparing patient groups in the Kaplan–Meier analyses
with P values less than 0.05 considered statistically significant.
TABLE 1 The stratification and CNS-directed irradiation of the high-risk patients treated onNOPHOALL-92 and ALL-2000 protocols
Prophylactic CNS-RT Therapeutic CNS-RT
ALL-92 ALL-2000 ALL-2000 ALL-2000
Risk features Age≥5 years and
- Lymphomatous features
- D15 BMM3
- D29 BM≥M2
- T-ALLwith other
high-risk features*
Any age and
-WBC≥200× 109 l–1
- BMD29M3
- t(9;22)(q34;q11)
- t(4;11)(q21;q23)
- Low hypodiploidy** or
≥5 years and
-WBC 100—200× 109 l–1
- T-ALL andmediastinal mass
Any age, CNS3 ≥5 years and CNS3
CNS-RT dose Cranial 18 Gy Cranial 18 Gy Cranial 24
Gy/spinal 12 Gy
Cranial 24 Gy
*High-risk features in these protocols were CNS3, WBC ≥50 × 109 l–1, T-cell immunophenotype, lymphomatous features, testicular leukemia, or slow
response (day15marrowM3and/or day29marrow≥M2), high-risk cytogenetics,whichwere inALL-92 trial t(9;22)(q34;q11),MLL rearrangements (11q23),
(22q-), t(8;14)(q24;q32), t(2;8)(p12;q24), or t(8;22)(q24;q11), and in ALL-2000 trial t(9;22)(q34;q11), t(4;11)(q21;q23), t(1;19)(q23;p13.3), and hypodiploidy
(modal chromosomal number<45).
**Low hypodiploidy,<34 chromosomes.
D, day; Gy, Gray.
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Fifty-twopatients (including fourCNS3patients) didnot reach com-
plete remissionby theendof induction. Thus, thefinal studypopulation
for the analyses of the role of CNS-RT consisted of the 783 high-risk-
patients (including 52 CNS3 patients) who achieved CR1 by the end of
induction (Fig. 1).
Poisson regression was utilized to model mortality and incidence
rates.CNS-RTandHSCT inCR1were includedasdiscrete time-varying
covariates. When the endpoints were relapse, DCR1 or SMN, compet-
ing risks regression was applied to estimate cumulative incidence and
sub-hazard ratios. We observed a significant lack of proportionality
of the hazard curves for mortality over time before and after irradi-
ation. In all regression models, the standard errors of the regression
coefficients were estimated by applying a cluster-robust estimator.18
To adjust for factors associated with outcome, we included age,
immunophenotype, WBC at diagnosis, and cytogenetics in the regres-
sion models. Protocol was added to the final regression model to
adjust for the differences in treatment and adherence to CNS-RT
recommendations during the trial periods.
The cytogenetic analyses were not always successful and thus
these data were incomplete. Accordingly, we divided the cytogenetic
results into four groups representing patients with normal karyotype,
favorable (t(12;21)(p12;q22), high hyperdiploidy with modal chro-
mosomal number ≥50), unfavorable (MLL rearrangements (11q23),
t(9;22) (q34;q11) or hypodiploidy), or undefined (missing/failed/other)
togenetics.
3 RESULTS
3.1 Patient characteristics and outcome by CNS
status
CNS3 was detected in 56 of 2,735 patients (2.0%) and, accordingly,
in 56 of 835 high-risk patients (6.7%). The majority of the CNS3
patients (51.8%) were those with WBC below 50 × 109 l–1 (Table 2).
No statistically significant differences were observed in the incidence
of CNS3 among the high-risk patients when stratified by gender,
age, or cytogenetics. Also, the proportion of patients with CNS3 was
the same between pre-B and T-ALL, 36 of 549 (6.6%) and 18 of 256
(7.0%), respectively. Complete remission rate, OS, EFS, and cumulative
incidence of relapse were similar in patients with or without CNS3
(Table 2). Induction failures occurred in four of the 56 CNS3 patients.
Among the 15CNS3 patientswho relapsed, seven had aCNS-involving
relapse. All of the CNS-involving relapses among the CNS3 patients
were isolatedCNS relapses, but only 22 of the 220 (10%)were isolated
CNS relapses in the no central nervous system leukemia (CNS1-2)
group.
3.2 The impact of irradiation on events
Of the 783 patients in CR1, 169 (22%) underwent CNS-RT (Table 3).
The proportion of patients undergoing CNS-RT was higher during
ALL-92 compared with ALL-2000, being 27% (118/439) versus 15%
(51/344) (P< 0.001).
TABLE 2 Clinical characteristics, events, and outcomebyCNS3 sta-
tus (CNS1-2 vs. CNS3) in high-riskALLpatients treatedon theNOPHO
ALL-92 and ALL-2000 protocols
CNS1-2,
n= 779
CNS3,
n= 56 P value
Age NS
1–4 years 357 (46%) 22 (39%)
5–9 years 229 (29%) 14 (25%)
10–14 years 193 (25%) 20 (36%)
Gender NS
Male 481 (62%) 34 (61%)
Female 298 (38%) 22 (39%)
WBC (x109 l–1) 0.001
≤50.0 286 (37%) 29 (52%)
50.1–100.0 240 (31%) 5 (9%)
100.1–200.0 137 (17%) 8 (14%)
≥200.1 116 (15%) 14 (25%)
Immunophenotype NS
BCP 513 (66%) 36 (64%)
T-ALL 258 (33%) 20 (36%)
Unknown 8 (1%) 0
Cytogeneticsa NS
Normal karyotype 201 (26%) 18 (32%)
Favorable 170 (22%) 11 (20%)
Unfavorable 106 (13%) 5 (9%)
Other 302 (39%) 22 (39%)
Primary events NS
Induction failure 20 (3%) 4 (7%)
Resistant disease 28 (4%) 0
CR1 479 (61%) 34 (61%)
Relapse 220 (28%) 15 (27%)
DCR1 24 (3%) 3 (5%)
SMN 8 (1%) 0
Survival (±SE) NS
5-year EFS 64.1%± 1.7 60.6%± 6.5
10-year EFS 63.0%± 1.7 60.6%± 6.5
5-year OS 76.7%± 1.5 71.3%± 6.1
10-year OS 74.4%± 1.6 69.3%± 6.2
aFavorable: t(12;21)(p12;q22), high hyperdiploidy with modal chromo-
somal number ≥50; Unfavorable: t(9;22)(q34;q11), MLL rearrangements
(11q23), hypodiploidy (modal chromosomal number <45); Other: Non-
stratifying or non-specific cytogenetic aberrations andmissing values.
The CNS status was defined as CNS1, no leukocytes in CSF, CNS2, 1–5
mononuclear cells/𝜇l of CSF, and CNS3, ≥5 mononuclear cells/𝜇l of CSF.
BCP, B-cell precursor.
Nonadherence to the irradiation recommendations was observed
(Supplementary Table S1). Of the 52CNS3-patients in remission at the
end of induction, only 16 underwent CNS-RT, all being at least 5 years
old. Thirteen of the 16 CNS3-patients received the dose prescribed in
the protocol, whereas three patients were irradiated with a reduced
dose. Eight patients in the prophylactic irradiation group received
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TABLE 3 Clinical characteristics of the irradiated andnonirradiated
high risk-patients
Nonirradiated,
n= 614 (78%)
Irradiated,
n= 169 (22%) P value
Age <0.001
1–4 years 353 (58%) 8 (5%)
5–9 years 145 (24%) 82 (48%)
10–14 years 116 (19%) 79 (47%)
Gender 0.043
Male 369 (60%) 116 (69%)
Female 245 (40%) 53 (31%)
WBC (x109 l–1) 0.001
≤50.0 216 (35%) 77 (45%)
50.1–100.0 203 (33%) 31 (18%)
100.1–200.0 102 (17%) 39 (23%)
≥200.1 93 (15%) 22 (14%)
Immunophenotype <0.001
BCP 457 (74%) 63 (37%)
T-ALL 156 (25%) 100 (59%)
Unknown 1 (0.2%) 6 (4%)
Cytogeneticsa <0.001
Normal karyotype 136 (22%) 66 (39%)
Favorable 155 (25%) 19 (11%)
Unfavorable 97 (16%) 7 (4%)
Other 231 (37%) 77 (46%)
CNS statusb 0.096
CNS1-2 578 (94%) 153 (91%)
CNS3 36 (6%) 16 (9%)
Treatment protocol <0.001
NOPHOALL-92 321 (52%) 118 (70%)
NOPHOALL-2000 293 (48%) 51 (30%)
HSCT in CR1 <0.001
Yes 107 (17%) 3 (2%)
No 507 (83%) 166 (98%)
Survival (±SE)
5-year EFS (%) 68.5%± 2.1 78.0%± 3.2 0.017
10-year EFS (%) 67.0%± 2.1 76.6%± 3.3
5-year OS (%) 82.8%± 1.7 83.9%± 2.8 NS
10-year OS (%) 79.3%± 1.9 83.9%± 2.8
aFavorable: t(12;21)(p12;q22), high hyperdiploidy with modal chromo-
somal number ≥50; Unfavorable: t(9;22)(q34;q11), MLL rearrangements
(11q23), hypodiploidy (modal chromosomal number<45); Other: nonstrat-
ifying or nonspecific cytogenetic aberrations andmissing values.
bCNS1, no leukocytes in CSF; CNS2, 1–5 mononuclear cells/𝜇l of CSF,
CNS3,≥5mononuclear cells/𝜇l of CSF.
A total of 783 patients were treated in NOPHO ALL-92 or NOPHO ALL-
2000 trials. Patients with induction failure or resistant disease have been
excluded (N= 52). BCP, B-cell precursor.
irradiation at a higher dose than indicated in the protocol. Three
patients who underwent HSCT in CR1 had received CNS-RT, all
CNS1-2. Among the 36 patients who were not irradiated, 16 were 5
years or older, of whom six underwent HSCT in CR1.
TABLE 4 Estimated HRs for OS and EFS in high-risk ALL patients
treated onNordic protocols (NOPHOALL-92 andNOPHOALL-2000)
OS (HRs) EFS (HRs)
Crude A B Crude A B
Irradiation
Baseline change
per year
0.79*** 0.80*** 0.80*** 0.71** 0.71** 0.71***
Direct impact of
CNS-RT
0.75 0.69 0.69 0.59* 0.58* 0.58*
HSCT in CR1 1.37 1.23 1.05 1.05 1.03 0.92
Age
5–9 years 1.64** 1.60* 1.14 1.19
>10 years 1.69** 1.59* 1.02 1.06
WBC≥100× 109 l–1 1.46* 1.56***
Cytogeneticsa
Favorable 0.74 1.05
Unfavorable 1.64* 1.39
Other 1.30 1.31
Immunophenotype
T-ALL 1.07 0.92
CNS3 1.18 1.11
NOPHOALL-92 1.52* 1.29*
aFavorable: t(12;21)(p12;q22), high hyperdiploidy with modal chromo-
somal number ≥50; Unfavorable: t(9;22)(q34;q11), MLL rearrangements
(11q23), hypodiploidy (modal chromosomal number<45); Other: nonstrat-
ifying or nonspecific cytogenetic aberrations andmissing values.
*P< 0.05; **P< 0.01; ***P< 0.001.
Due to theprotocol stratification, the irradiatedpatientswere older
and had more often T-ALL compared with the nonirradiated patients.
Among the T-ALL patients, 101 of 256 (39.5%) received CNS-RT com-
pared with 63 of the 520 (12.1%) pre-B ALL patients. Both patients
with unfavorable and favorable cytogenetics were more numerous in
the nonirradiated group (Table 3). This could be explained by the higher
proportion of patients with unfavorable cytogenetics who underwent
HSCT in CR1 instead of CNS-RT and the higher proportion of T-ALL
(normallywithout stratifying cytogenetic aberrations) in the irradiated
group.
In total, 40 eventswereobservedamong the169 irradiatedpatients
(37 relapses, two DCR1, and one SMN) and 230 events (198 relapses,
25 DCR1s, and seven SMN) among the 614 nonirradiated patients
(Supplementary Table S2). Relapses occurred in six (37.5%) of the 16
patients with CNS3 status at diagnosis who received CNS-RT com-
pared with nine (25.0%) of the 36 patients with CNS3 who did not
receive CNS-RT (P = 0.358). Among the nonirradiated patients who
did not undergo HSCT in CR1 (n = 507), 183 events occurred (167
relapses, 15 DCR1, and one SMN).
The EFS at 10 years was significantly higher in irradiated (76.6
± 3.3%) than in the nonirradiated (67.0 ± 2.1) patients (P = 0.017)
(Table 3). Since there was a statistically significant difference in the
distribution of baseline characteristics between the two groups, the
data were analyzed with adjusted regression models. The first regres-
sion model estimated the unadjusted hazard ratio (HR) for CNS-RT
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TABLE 5 Competing risks regression estimating sub-HRs for relapse, isolated BM relapse, CNS-involving relapse, and isolated CNS relapse
Relapse1 Isolated BM relapse2 CNS-involving relapse3 Isolated CNS relapse4
Crude A B Crude A B Crude A B Crude A B
CNS-RT 0.49** 0.42*** 0.47** 0.42*** 0.39*** 0.50* 0.46* 0.39* 0.34** 0.40 0.23* 0.12**
HSCT in CR1 1.02 0.94 0.82 1.08 1.01 0.92 0.55 0.50* 0.40* 0.43 0.30 0.15*
Age
5–9 years 1.32 1.44 1.22 1.40 1.32 1.37 3.53* 3.99*
>10 years 1.36 1.40 1.25 1.38 1.39 1.44 3.87* 4.06*
WBC≥100× 109 l–1 1.68** 1.41 1.85 2.63
Cytogeneticsa
Favorable 1.41 1.61 1.46 1.10
Unfavorable 1.50 1.67 0.91 1.90
Other 1.67* 1.89* 1.99* 2.04
T-ALL 0.70 0.47** 1.39 1.88
CNS3 1.10 1.01 1.62 7.09***
NOPHOALL-92 0.74 0.67 1.02 2.04
*P< 0.05; **P< 0.01; ***P< 0.001.
Competing events: 1DCR1 and SMN; 2DCR1, SMN, combined, and isolated extramedullary relapses; 3DCR1, SMN, and non-CNS-involving relapses; 4DCR1,
SMN, combined, and isolated BM relapses.
aFavorable: t(12;21)(p12;q22), high hyperdiploidy with modal chromosomal number ≥50; Unfavorable: t(9;22)(q34;q11), MLL rearrangements (11q23),
hypodiploidy (modal chromosomal number<45); Other: nonstratifying or nonspecific cytogenetic aberrations andmissing values.
(crude), the second model included age (model A), and the third model
included multiple covariates (model B) (Table 4). The annual risk of
an event decreased by 29% in nonirradiated patients (crude). When
the patient received irradiation, the risk of events decreased by addi-
tional 42% (HR 0.58, P < 0.05) in the age- and multivariable-adjusted
models. Taking into account both the baseline risk and the protective
effect of CNS-RT plus other baseline factors in model B, the annual
risk for any event was 12% (= 0.42 × 0.29) in the irradiated group
but 29% in the nonirradiated group. Other independent risk factors in
model B were hyperleukocytosis (WBC ≥100 × 109 l–1) at diagnosis
(HR 1.56, P < 0.001) and treatment according to the ALL-92 protocol
(HR 1.29, P < 0.05). In an alternative model (not shown) only includ-
ing patients 5 years or older (n = 384), CNS-RT was the only statis-
tically significant factor, reducing the risk of adverse events by 65%
(P< 0.05).
In the competing-risks analysis where relapse was the event of
interest and DCR1 and SMN were the competing events, the risk
of relapses was considerably lower in the irradiated group (Table 5).
We estimated the sub-HRs with three separate models, all showing
reduced risk for relapse in patients undergoing CNS-RT. In the age-
adjusted model (model A), the sub-HR was 0.42 (P < 0.001) and in
model B, where adjustments were made for multiple baseline factors,
the sub-HRwas0.47 (P<0.01).WBC100×109 l–1 or higher at diagno-
sis (HR 1.68, P < 0.01) and cytogenetics other than favorable or unfa-
vorable (HR 1.67, P< 0.05) were independent risk factors for relapse.
The risk of isolated BM relapses, CNS-involving relapses and iso-
lated CNS relapses were significantly lower in the irradiated group
compared with that in the nonirradiated group, sub-HRs 0.50 (P <
0.05), 0.34 (P < 0.01), and 0.12 (P < 0.01), respectively (Table 4). We
observed a decreased risk of CNS-involving relapses (HR 0.40, P <
0.05) and isolated CNS relapses (HR 0.15, P < 0.05) among patients
who underwent HSCT in CR1. Involvement of the CNS was a very
strong independent risk factor for isolated CNS relapse (HR 7.09, P <
0.001). The favorable effect of CNS-RT on relapse rate persisted even
in separate analyses of pre-B and T-ALL patients.
3.3 The impact of irradiation onOS
The OS estimated with the Kaplan–Meier method was similar in high-
risk ALL patients with or without CNS-RT (10 year OS 79.3 ± 1.9 vs.
83.9 ± 2.8, P = n.s.) (Table 3). In the multivariable Poisson regression
analysis, the risk of death decreased by 20% every year in the nonirra-
diated group during the follow-up time (baseline) (Table 4). The risk of
death decreased by additional 36% (HR 0.64, P = n.s.), in the adjusted
models, in patients who received CNS-RT, but the survival advantage
was not statistically significant. Independent factors for death were
age 5–10 years (HR 1.60, P < 0.05), age 10 years or older (HR 1.59,
P < 0.05), hyperleukocytosis (HR 1.46, P < 0.05), unfavorable cytoge-
netics (HR 1.64, P < 0.05), and ALL-92 protocol treatment (HR 1.52,
P< 0.05).
4 DISCUSSION
In this population-based study, we show that, although CNS involve-
ment at diagnosis does not decrease OS, it still remains as an inde-
pendent risk factor for isolated CNS relapse in children with high-risk
ALL patients treated with modern ALL therapy. However, due to the
low number of CNS3 patients who underwent CNS-RT in our study,
we were unable to answer the question whether CNS-RT is beneficial
for CNS3 patients. Despite systemic high-dose therapy includingMTX
and cytarabine, intensive IT therapy, and even CNS-RT prescribed to
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a subgroup of children over 5 years of age in the NOPHO protocols,
the cumulative incidence of isolated CNS relapse was as high as 47%
in CNS3 patients compared with 10% in the remaining patients. How-
ever, as CNS3 status was not a threat to OS, this finding challenges the
role of permanently damaging therapeuticmodalities in CR1, including
irradiation, in ALL patients of all ages.
Weobserved thatCNS-RThas a clear therapeutic effect inALL. Bet-
ter EFS was mainly a result of a reduced incidence of relapse. Impor-
tantly, CNS-RT did not increase the rate of SMN and DCR1 compared
with the nonirradiated patients, although the follow-up time may be
too short for detecting all types of secondary tumors, such as basal cell
carcinoma, meningioma, and glioblastoma.
Better EFS did not result in increased OS in irradiated patients
stratified to high-risk-therapy by WBC, cytogenetics, CNS3, or poor
response to therapy. These data are supported by other studies.19,20
In NOPHO, these data have resulted in omission of irradiation for all
patients in CR1, including CNS3, and CNS-RT is reserved for those
with a CNS-involving relapse.13 Even in subgroups, such as T-ALL with
hyperleukocytosis, who have a CNS relapse rate of up to 10–20%, 80%
patients will avoid CNS-RTwith this approach.
The methods to compensate for the effect of CNS-RT in the
ALL therapy have been IT and systemic chemotherapy. Traditionally,
NOPHO protocols have included a substantial number of high-dose
MTX courses,21,22 high-dose cytarabine, and intensive IT chemother-
apy, as was the case in the ALL-92 and ALL-2000 protocols. A meta-
analysis of 47 randomized trials showed thatCNS-RT resulted inbetter
protection against CNS-involving relapse but showed no EFS advan-
tage as compared with IT therapy, given that the IT therapy comprised
of sufficient number of injections.20 In comparison with IV high-dose
MTX (at 0.5–8 g/m²), CNS-RT reduced the CNS relapse rate but had
less effect on non-CNS relapse resulting in similar EFS rate.20 In con-
trast, IT triples are better for preventing CNS relapses, but protocols
with IT MTX have lower frequency of systemic relapses.20 The opti-
mal combination of IT and systemic chemotherapy is still an elusive tar-
get. New agents, including liposomal cytarabine,23 with long-acting IT
effect may contribute to better protection against CNS relapses. Data
are still pending whether new diagnostic methods more sensitive than
cytospin, such as flow cytometry, may help in stratifying patients to
more intensive CNS-directed therapy and result in better CNS control
in the long run.
A meta-analysis covering 28 studies from late 1980s to 2004,
reported that ALL survivors who had undergone CNS-RT consis-
tently experienced significant deficits in intellectual functioning, aca-
demic achievement, and specific neurocognitive abilities compared
with control groups.24 In addition to the impairment of the neurocog-
nitive achievements, the multiple long-term late effects in endocrine
function25 and increased risk of secondary brain tumors26,27 have led
many other ALL study groups to avoid prophylactic CNS-RT to the
developing brain or even therapeutic CNS-RT in CNS3 patients aswell.
Protocol adherence to the recommendation forCNS-RTwasaprob-
lem in this study. The negative attitude toward irradiation among clin-
icians was obvious judging from the variation in the interpretation of
the protocol irradiation guidelines. Not all patients eligible for CNS-RT
received irradiation according to the protocol and, interestingly, some
received CNS-RT, although it was not recommended in the protocol.
We analyzed the cohort on “as-treated” basis taking into account com-
peting events and time-dependent factors and adjusted for potential
confounders in an attempt to estimate the actual effect of CNS-RT on
outcome. We chose regression analyses instead of stratified survival
analyses, since the groups were unbalanced and adjustments for base-
line factors were therefore necessary. Our study is population-based
with a long follow-up time, only fewpatientswere lost to follow-up, and
we performed thorough annual review and registration of the follow-
up data, all which are the strengths of this study. In our study settings,
the protocol violations and the respective design were hard to com-
pensate for, but with our statistical approach and adapted exclusions,
we attempted to make the most correct assumptions from our results.
Since the majority of the patients irradiated were over 5 years of age,
our results can be best adapted to this age group.
In conclusion, CNS-RT, either therapeutic or prophylactic,
decreases the overall frequency of relapses in high-risk ALL patients,
with particularly beneficial effect on the CNS protection against
relapse. This result was achieved without an increase in treatment-
related mortality or second malignancies. However, CNS-RT did not
result in survival advantage. Thus, in the current Nordic ALL-2008
protocol, CNS-RT has been omitted for all patients.
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